Discordance between beliefs and recommendations of gynecologic oncologists in ovarian cancer management

International Journal of Gynecological Cancer

Volumn 14, Issue 6, 2004, Pages 1055-1062

  Chen, L ^a,b   Learman, L A ^a   Weinberg, V ^a   Powell, C B ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE   (United States)

Author keywords

Chemotherapy; Decision making; Ovarian cancer; Surgery

Indexed keywords

ADJUVANT CHEMOTHERAPY; CANCER CHEMOTHERAPY; CANCER SURGERY; CONFERENCE PAPER; FEMALE; HUMAN; INTERMETHOD COMPARISON; MALE; MEDICAL DECISION MAKING; NORMAL HUMAN; OVARY CANCER; PRIORITY JOURNAL; QUESTIONNAIRE; RECURRENT CANCER; TREATMENT PLANNING;

COMBINED MODALITY THERAPY; DECISION MAKING; FEMALE; GYNECOLOGY; HUMANS; MALE; MEDICAL ONCOLOGY; MIDDLE AGED; OVARIAN NEOPLASMS; PATIENT CARE PLANNING; PHYSICIAN'S PRACTICE PATTERNS; QUESTIONNAIRES; UNITED STATES;

EID: 10044268451     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1048-891X.2004.14602.x     Document Type: Conference Paper

References (20)

1. Morgan RJ Jr, Copeland L, Gershenson D et al. NCCN Ovarian Cancer Practice Guidelines. The National Comprehensive Cancer Network. Oncology (Huntingt) 1996;10:293-310.
2. Griffiths CT. Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Natl Cancer Inst Monogr 1975;42:101-4.
3. Hacker NF, Berek JS, Lagasse LD, Nieberg RK, Elashoff RM. Primary cytoreductive surgery for epithelial ovarian cancer. Obstet Gynecol 1983;61:413-20.
4. Schwartz PE, Rutherford TJ, Chambers JT, Kohorn EI, Thiel RP. Neoadjuvant chemotherapy for advanced ovarian cancer: long-term survival. Gynecol Oncol 1999;72:93-9.
5. Kuhn W, Rutke S, Spathe K et al. Neoadjuvant chemotherapy followed by tumor debulking prolongs survival for patients with poor prognosis in International Federation of Gynecology and Obstetrics Stage HIC ovarian carcinoma. Cancer 2001;92:2585-91.
6. Janicke F, Holscher M, Kuhn W et al. Radical surgical procedure improves survival time in patients with recurrent ovarian cancer. Cancer 1992;70:2129-36.
7. Bristow RE, Lagasse LD, Karlan BY. Secondary surgical cytoreduction for advanced epithelial ovarian cancer. Patient selection and review of the literature. Cancer 1996;78:2049-62.
8. Munkarah A, Levenback C, Wolf JK et al. Secondary cytoreductive surgery for localized intra-abdominal recurrences in epithelial ovarian cancer. Gynecol Oncol 2001;81:237-41.
9. Covens AL. A critique of surgical cytoreduction in advanced ovarian cancer. Gynecol Oncol 2000;78:269-74.
10. Mackillop WJ, Ward GK, O'Sullivan B. The use of expert surrogates to evaluate clinical trials in non-small cell lung cancer. Br J Cancer 1986;54:661-7.
11. Moore MJ, O'Sullivan B, Tannock IF. How expert physicians would wish to be treated if they had genitourinary cancer. J Clin Oncol 1988;6:1736-45.
12. Belanger D, Moore M, Tannock I. How American oncologists treat breast cancer: an assessment of the influence of clinical trials. J Clin Oncol 1991;9:7-16.
13. Bristow RE, Montz FJ, Lagasse LD, Leuchter RS, Karlan BY. Survival impact of surgical cytoreduction in stage IVepithelial ovarian cancer. Gynecol Oncol 1999;72:278-87.
14. Liu PC, Benjamin I, Morgan MA, King SA, Mikuta JJ, Rubin SC. Effect of surgical debulking on survival in stage IV ovarian cancer. Gynecol Oncol 1997;64:4-8.
15. Curtin JE Malik R, Venkatraman ES, Barakat RR, Hoskins WJ. Stage IV ovarian cancer: impact of surgical debulking. Gynecol Oncol 1997;64:9-12.
16. Munkarah AR, Hallum AV III, Morris M et al. Prognostic significance of residual disease in patients with stage IV epithelial ovarian cancer. Gynecol Oncol 1997;64:13-7.
17. Chi DS, Venkatraman ES, Masson V, Hoskins WJ. The ability of preoperative serum CA-125 to predict optimal primary tumor cytoreduction in stage III epithelial ovarian carcinoma. Gynecol Oncol 2000;77:227-31.
18. van der Burg ME, van Lent M, Buyse M et al. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med 1995;332:629-34.
19. Rose P, Nerenstone S, Brady M, Clarke-Pearson G, Olt S. A phase III randomized study of interval secondary cytoreduction in patients with advanced stage ovarian carcinoma with suboptimal residual disease: a Gynecologic Oncology Group Study. Proceedings of the American Society of Clinical Oncology. Orlando, FL: American Society of Clinical Oncology, 2002 (Abstract no. 802).
20. Bruera E, Sweeney C, Calder K, Palmer L, Benisch-Tolley S. Patient preferences versus physician perceptions of treatment decisions in cancer care. J Clin Oncol 2001;19: 2883-5.